Alain C. Jung

TL;DR: Results tie ELK3 into the hypoxia response pathway through an oncogenic microRNA and into a circuit implicated in the dynamics of the hypoxic response, which could be important for the development of new treatments for a range of pathologies.

TL;DR: The major therapeutic breakthrough worked by Immune Checkpoint Inhibitors (ICIs) blocking the PD-1/PD-L1 axis is described, which has doubled the 2-year survival rate thanks to long lasting responses with a favorable toxicity profile.

TL;DR: It is shown that “R1” patients do not or at very low level express caveolin-1 (Cav1), which enables cells to undergo epithelial-mesenchymal transition (EMT), and a new target, α5β1 integrin is uncovered, which might not only prevent metastasis of HNSCC but also delay the development of the primary tumor by reducing tumor cell viability.

TL;DR: HPV-related OSCC display lower tumour hypoxia, which could be linked to the distinct intrinsic abilities of HPV-positive tumour cells to adapt to Hypoxia and to their better prognosis.

TL;DR: Results indicate that NAE1/APP-BP1 and NEDDylation are invovled in modulating p53 activity and regulating its role in the response of cells to ionizing radiation.